Defining the role of repaglinide in the management of type 2 diabetes mellitus: A review

American Journal of Cardiovascular Drugs

Volumn 7, Issue 5, 2007, Pages 319-335

  Johansen, Odd Erik ^a   Birkeland, Kåre I ^b  

^a Novo Nordisk Scandinavia AS   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Glibenclamide, therapeutic use; Glimepiride, therapeutic use; Glipizide, therapeutic use; Insulin suspension isophane, therapeutic use; Metformin, therapeutic use; Nateglinide, therapeutic use; Pioglitazone, therapeutic use; Repaglinide, adverse reactions

Indexed keywords

ACARBOSE; ADIPONECTIN; ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ISOPHANE INSULIN; LIPID; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ABDOMINAL PAIN; ATHEROSCLEROSIS; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; GERIATRICS; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLAMMATION; INTIMA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MEDLINE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PREGNANCY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBOCYTE ACTIVATION; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 35448987730     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200707050-00002     Document Type: Review

References (145)

1. Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47: 345-51
2. Owens DR, Luzio SD, Ismail I, et al. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care 2000; 23: 518-23
3. Abbink EJ, van der Wal PS, Sweep CG, et al. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta cell secretion after glucose stimulation. Diabetes Metab Res Rev 2004; 20: 466-71
4. DeFronzo RA. Lilly lecture 1987: the triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-87
5. U. K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44: 1249-58
6. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34
7. Lehto S, Ronnemaa T, Pyorala K, et al. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 1996; 27: 63-8
8. Ness J, Aronow WS, Ahn C. Risk factors for symptomatic peripheral arterial disease in older persons in an academic hospital-based geriatrics practice. J Am Geriatr Soc 2000; 48: 312-4
9. Muller WA. Diabetes mellitus: long time survival. J Insur Med 1998; 30: 17-27
10. NIDDK. Diabetes statistics. NIH publication no. 06-3892 [online]. Available from URL: http://diabetes.niddk.nih.gov [Accessed 2007 Aug 29]
11. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-83
12. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascu-lar disease in type II diabetes: the epidemiological evidence. Diabetologia 2001; 44: 2107-14
13. Gao W, Qiao Q, Tuomilehto J. Post-challenge hyperglycaemia rather than fasting hyperglycaemia is an independent risk factor of cardiovascular disease events. Clin Lab 2004; 50: 609-15
14. Shiraiwa T, Kaneto H, Miyatsuka T, et al. Postprandial hyperglycemia is a better predictor of the progression of diabetic retinopathy than HbA1c in Japanese type 2 diabetic patients. Diabetes Care 2005; 28: 2806-7
15. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006; 29: 1486-90
16. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-12
17. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43
18. Cook MN, Girman CJ, Stein PP, et al. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 2005; 28: 995-1000
19. International Diabetes Federation. The IDF global guideline for type 2 diabetes [online]. Available from URL: http://www.idf.org [Accessed 2007 Aug 29]
20. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 2007; 30 Suppl. 1: S4-41
21. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2006; 49: 1711-21
22. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-30
23. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management - 2000 update. Endocr Pract 2000; 6: 43-84
24. Task FM, Ryden L, Standl E, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: the Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136
25. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-42
26. Resnick HE, Foster GL, Bardsley J, et al. Achievement of American Diabetes Association Clinical Practice Recommendations Among U.S. Adults With Diabetes, 1999-2002: The National Health and Nutrition Examination Survey. Diabetes Care 2006; 29: 531-7
27. Liebl A, Mata M, Eschwege E, et al. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 2002; 45: S23-8
28. Olivarius NF, Beck-Nielsen H, Andreasen AH, et al. Randomised controlled trial of structured personal care of type 2 diabetes mellitus. BMJ 2001; 323: 970-5
29. Renders CM, Valk GD, Griffin S, et al. Interventions to improve the management of diabetes mellitus in primary care, outpatient and community settings. Cochrane Database Syst Rev 2001; (1): CD001481
30. Menard J, Payette H, Baillargeon JP, et al. Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial. CMAJ 2005; 173: 1457-66
31. Gaede P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-22
32. Glazier RH, Bajcar J, Kennie NR, et al. A systematic review of interventions to improve diabetes care in socially disadvantaged populations. Diabetes Care 2006; 29: 1675-88
33. Johansen OE, Gullestad L, Blaasaas KG, et al. Effects of structured hospital-based care vs. standard care for type 2 diabetes: the Asker and Baerum Cardiovascular Diabetes Study, a randomized trial. Diabet Med 2007; 24: 1019-27
34. Vila-Carriles WH, Zhao G, Bryan J. Defining a binding pocket for sulfonylureas in ATP-sensitive potassium channels. FASEB J 2007; 21: 18-25
35. Wolffenbuttel BH. Repaglinide: a new compound for the treatment of patients with type 2 diabetes. Neth J Med 1999; 55: 229-34
36. Hansen AM, Christensen IT, Hansen JB, et al. Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1. Diabetes 2002; 51: 2789-95
37. Gromada J, Dissing S, Kofod H, et al. Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells. Diabetologia 1995; 38: 1025-32
38. Malaisse WJ. Regulation, perturbation, and correction of metabolic events in pancreatic islets. Acta Diabetol 1996; 33: 173-9
39. Viñambres C, Villanueva-Peñacarrillo ML, Valverde I, et al. Repaglinide preserves nutrient-stimulated biosynthetic activity in rat pancreatic islets. Pharmacol Res 1996; 34: 83-5
40. Esposito K, Giugliano D, Nappo F, et al. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004; 110: 214-9
41. Abbatecola AM, Rizzo MR, Barbieri M, et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006; 67: 235-40
42. Derosa G, Mugellini A, Ciccarelli L, et al. Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Res Clin Pract 2003; 60: 161-9
43. Derosa G, Mugellini A, Ciccarelli L, et al. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther 2003; 25: 472-84
44. Rizzo MR, Barbieri M, Grella R, et al. Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes: a short term study. Diabetes Metab 2004; 30: 81-9
45. Lund SS, Tarnow L, Stehouwer CDA, et al. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. Diabetes Obes Metab 2007; 9: 394-407
46. Rizzo MR, Barbieri M, Grella R, et al. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. Diabetes Metab 2005; 31: 255-60
47. Manzella D, Grella R, Abbatecola AM, et al. G. Repaglinide administration improves brachial reactivity in type 2 diabetic patients. Diabetes Care 2005; 28: 366-71
48. Bleskestad IH, Birkeland KI. Differences between oral antidiabetics. Tidsskr Nor Lægeforen 2003; 123: 808-9
49. Goldberg RB, Einhorn D, Lucas CP, et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998; 21: 1897-903
50. Chuang LM, Tai TY, Juang JH, et al. Effect of a prandial glucose regulator (NovoNorm®) at two doses (0.5mg and 2.0mg) on glycemic control in type 2 diabetes in Taiwan. JAMA SE Asia 1999; 15: 22-5
51. Jovanovic L, Dailey III G, Huang WC, et al. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol 2000; 40: 49-57
52. Van Gaal LF, Van Acker KL, De Leeuw IH. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes. Diabetes Res Clin Pract 2001; 53: 141-8
53. Moses RG, Gomis R, Frandsen KB, et al. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes Care 2001; 24: 11-5
54. Damsbo P, Marbury TC, Hatorp V, et al. Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes. Diabetes Res Clin Pract 1999; 45: 31-9
55. Schmitz O, Lund S, Andersen PH, et al. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide. Diabetes Care 2002; 25: 342-6
56. Kølendorf K, Eriksson J, Birkeland KI, et al. Dose titration of repaglinide in patients with inadequately controlled type 2 diabetes. Diabetes Res Clin Pract 2004; 64: 33-40
57. Gerstein HC, Garon J, Joyce C, et al. Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated type 2 diabetes: a randomized controlled clinical trial. Diabet Med 2004; 21: 1200-3
58. Rosak C, Hofmann U, Paulwitz O. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application. Diabetes Nutr Metab 2004; 17: 137-42
59. Wolffenbuttel BH, Nijst L, Sels JP, et al. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. Eur J Clin Pharmacol 1993; 45: 113-6
60. Marbury T, Huang WC, Strange P, et al. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999; 43: 155-66
61. Wolffenbuttel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 1999; 22: 463-7
62. Landgraf R, Bilo HJ, Müller PG. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 1999; 55: 165-71
63. Yngen M, Ostenson CG, Hjemdahl P, et al. Meal-induced platelet activation in type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide. Diabet Med 2006; 23: 134-40
64. Papa G, Fedele V, Rizzo MR, et al. Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: a randomized, open-label, two-period, cross-over trial. Diabetes Care 2006; 29: 1918-20
65. Madsbad S, Kilhovd B, Lager I, et al. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study. Diabet Med 2001; 18: 395-401
66. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999; 22: 119-24
67. Moses R. Repaglinide in combination therapy with metformin in type 2 diabetes. Exp Clin Endocrinol Diabetes 1999; 107 Suppl. 4: S136-9
68. Raskin P, Jovanovic L, Berger S, et al. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes. Diabetes Care 2000; 23: 979-83
69. Raskin P, McGill J, Saad MF, et al. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone. Diabet Med 2004; 21: 329-35
70. Jovanovic L, Hassman DR, Gooch B, et al. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res Clin Pract 2004; 63: 127-34
71. Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004; 27: 1265-70
72. Li J, Tian H, Li Q, et al. Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients: a randomized controlled double-blind and double-dummy multicentre clinical trial. Diabetes Obes Metab 2007; 9: 558-65
73. Singhal P, Caumo A, Cobelli C, et al. Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production. Metabolism 2005; 54: 79-84
74. Raskin P, Klaff L, McGill J, et al. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003; 26: 2063-8
75. Panelo A, Wing JR, for the AGEE-1272 study group. Repaglinide/bedtime NPH insulin Is comparable to twice-daily NPH insulin. Diabetes Care 2005; 28: 1789-90
76. Ozbek M, Erdogan M, Karadeniz M, et al. Preprandial repaglinide decreases exogenous insulin requirements and HbA1c in type 2 diabetic patients taking intensive insulin treatment. Acta Diabetol 2006; 43: 148-51
77. Furlong NJ, Hulme SA, O'Brien SV, et al. Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy. Diabetes Care 2002; 25: 1685-90
78. Furlong NJ, Hulme SA, O'Brien SV, et al. Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents. Diabet Med 2003; 20: 935-41
79. Davies MJ, Thaware PK, Tringham JR, et al. A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin. Diabet Med 2007; 24: 714-9
80. Hussein Z, Wentworth JM, Nankervis AJ, et al. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. Med J Aust 2004; 181: 536-9
81. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89
82. Johansen OE, Jørgensen AP. Glitazone treatment of type 2 diabetes mellitus. Tidsskr Nor Laegeforen 2006; 126: 1928-30
83. Landgraf R, Frank M, Bauer C, et al. Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with type 2 diabetes. Int J Obes Relat Metab Disord 2000; 24 Suppl. 3: S38-44
84. de Luis DA, Aller R, Cuellar L, et al. Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24: 1844-5
85. Tankova T, Koev D, Dakovska L, et al. The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients. Diabetes Res Clin Pract 2003; 59: 43-9
86. Soegondo S, Subekti I, Luthariana L. The efficacy of repaglinide monotherapy and in combination with metformin in Indonesian type 2 diabetes mellitus patients. Acta Med Indones 2004; 36: 142-7
87. Shapiro MS, Abrams Z, Lieberman N. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus. Isr Med Assoc J 2005; 7: 75-7
88. Nattrass M, Lauritzen T. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of type 2 diabetes? Int J Obes Relat Metab Disord 2000; 24 Suppl. 3: S21-31
89. Leiter LA, Ceriello A, Davidson JA, et al. Postprandial glucose regulation: new data andnew implications. Clin Ther 2005; 27 Suppl. 2: S42-56
90. Fuchtenbusch M. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2000; 108: 151-63
91. Davies MJ. Insulin secretagogues. Curr Med Res Opin 2002; 18 Suppl. 1: s22-30
92. Owens DR. Repaglinide: prandial glucose regulator: a new class of oral antidiabetic drugs. Diabet Med 1998; 15 Suppl. 4: S28-36
93. Moses R. A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes. Expert Opin Pharmacother 2000; 1: 1455-67
94. Owens DR, McDougall A. Repaglinide: prandial glucose regulation in clinical practice. Diab Obes Metab 2000; 2 Suppl. 1: S43-8
95. Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 2001; 61: 1625-60
96. Landgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs Aging 2000; 17: 411-25
97. Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001; 358: 1709-16
98. Massi-Benedetti M, Damsbo P. Pharmacology and clinical experience with repaglinide. Expert Opin Investig Drugs 2000; 9: 885-98
99. Balfour JA, Faulds D. Repaglinide. Drugs Aging 1998; 13: 173-80
100. Black C, Donnelly P, McIntyre L, et al. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; 18; (2): CD004654
101. Owens DR. Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes. Eur J Clin Invest 1999; 29 Suppl. 2: 30-7
102. Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2003; 111: 405-14
103. Mafauzy M. Repaglinide versus glibenclamide treatment of type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract 2002; 58: 45-53
104. Cesur M, Corapcioglu D, Gursoy A, et al. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. Diabetes Res Clin Pract 2007; 75: 141-7
105. Anwar A, Azmi KN, Hamidon BB, et al. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan. Med J Malaysia 2006; 61: 28-35
106. Sari R, Balci MK, Akbas SH, et al. The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan. Endocr Res 2004; 30: 169-77
107. Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003; 26: 886-91
108. Schumacher S, Abbasi I, Weise D, et al. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 2001; 57: 147-52
109. Marbury TC, Ruckle JL, Hatorp V, et al. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 2000; 67: 7-15
110. Brassoe R, Elkmann T, Hempel M, et al. Fulminant lactic acidosis in two patients with Type 2 diabetes treated with metformin. Diabet Med 2005; 22: 1451-3
111. Gudmundsdottir H, Aksnes H, Heldal K, et al. Metformin and antihypertensive therapy with drugs blocking the renin angiotensin system, a cause of concern? Clin Nephrol 2006; 66: 380-5
112. Kazory A, Walsh K, Harman E, et al. Is metformin safe in patients with mild renal insufficiency? Diabetes Care 2007; 30: 444
113. Turk T, Pietruck F, Dolff S, et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant 2006; 6: 842-6
114. Backman JT, Kajosaari LI, Niemi M, et al. Cyclosporine a increases plasma concentrations and effects of repaglinide. Am J Transplant 2006; 6: 2221-2
115. Turk T, Witzke O. Pharmacological interaction between cyclosporine a and repaglinide. Is it clinically relevant? Am J Transplant 2006; 6: 2223
116. Hatorp V, Huang WC, Strange P. Pharmacokinetic profiles of repaglinide in elderly Subjects with type 2 diabetes. J Clin Endocrinol Metab 1999; 84: 1475-8
117. Hatorp V, Huang WC, Strange P. Repaglinide pharmacokinetics in healthy young adult and elderly subjects. Clin Ther 1999; 21: 702-10
118. Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000; 151: 478-87
119. Lorenz MW, von-Kegler S, Steinmetz H, et al. Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke 2006; 37: 87-92
120. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296: 2572-81
121. Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 2002; 23: 831-4
122. Stern MP. Diabetes and cardiovascular disease. The 'common soil' hypothesis. Diabetes 1995; 44: 369-74
123. Johansen OE, Birkeland KI, Brustad E, et al. Undiagnosed dysglycaemia and inflammation in cardiovascular disease. Eur J Clin Invest 2006; 36: 544-51
124. Tomai F, Crea F, Gaspardone A, et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994; 90: 700-5
125. Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999; 20: 439-46
126. Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33: 119-24
127. Hueb W, Uchida AH, Gersh BJ, et al. Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris. Coron Artery Dis 2007; 18: 55-9
128. Evans MM, Ogston SA, Emslie-Smith A, et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006; 49: 930-6
129. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65
130. Fisman EZ, Tenenbaum A, Boyko V, et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 2001; 24: 151-8
131. Mannucci E, Monami M, Masotti G, et al. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diab Metab Res Rev 2004; 20: 44-7
132. Olsson J, Lindberg G, Gottsäter M, et al. Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 2000; 43: 558-60
133. Monami M, Luzzi C, Lamanna C, et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006; 22: 477-82
134. Iskit A, Erkent U, Ertunc C, et al. Glibenclamide attenuates the antiarrhythmic effect of endotoxin with a mechanism not involving K(ATP) channels. Vascul Pharmacol 2007; 46: 129-36
135. Meier JJ, Gallwitz B, Schmidt WE, et al. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 2004; 90: 9-12
136. Gulliford M, Latinovic R. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev 2004; 20: 239-45
137. Johnson JA, Simpson SH, Toth EL, et al. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 2005; 22: 497-502
138. Johnson JA, Majumdar SR, Simpson SH, et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-8
139. Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007; 30: 389-94
140. Stephan D. Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K-ATP channels. Diabetologia 2006; 49: 2039-48
141. Abbink EJ, Wollersheim H, Netten PM, et al. Microcirculatory effects of KATP channel blockade by sulphonylurea derivatives in humans. Eur J Clin Invest 2002; 32: 163-71
142. Smits P. Cardiovascular effects of sulphonylurea derivatives. Diabetologia 1997; 40 Suppl. 2: S160-1
143. Marshall V, Wilton L, Shakir S. Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study. Acta Diabetol 2006; 43: 6-13
144. Napoli A, Ciampa F, Colatrella A, et al. Use of repaglinide during the first weeks of pregnancy in two type 2 diabetic women. Diabetes Care 2006; 29: 2326-7
145. Mollar-Puchades MA, Martin-Cortes A, Perez-Calvo A, et al. Use of repaglinide on a pregnant woman during embryogenesis. Diabetes Obes Metab 2007; 9: 146-7